Pfizer-BioNTech’s COVID-19 vaccine shows 100% efficacy in young adolescents

Source: solarseven, Shutterstock


  • Pfizer-BioNTech’s COVID-19 vaccine has proved to be 100% effective in young adolescents (12-15 years) in Phase 3 clinical study.
  • The two partners plan to submit these data to the US FDA and the EMA in the next few weeks.
  • The companies are also conducting a global Phase 1/2/3 clinical trial to evaluate the vaccine in children aged 6 months-11 years.

Pfizer Inc (NYSE:PFE) and BioNTech SE (Nasdaq:BNTX), on 31 March 2021,  updated the market that their COVID-19 vaccine BNT162b2 demonstrated 100% efficacy and strong antibody responses in a Phase 3 trial in adolescents 12-15 years of age.

Source: Copyright © 2020 Kalkine Media Pty Ltd.

With experts highlighting that vaccinating children is vital to achieving herd immunity, this update comes as important positive news.

DO READ: Experts believe vaccinating children is key to achieving herd immunity

Top-line findings from pivotal Phase 3 trial in children

The companies stated that the vaccine was well-tolerated and exceeded the efficacy recorded earlier in vaccinated participants aged 16-25 years. These are top-line findings from a pivotal Phase 3 clinical trial, which is performed on 2,260 adolescents.

Interestingly, Pfizer and BioNTech plan to submit the trial findings to the Food and Drug Administration (FDA) for a requested amendment to the Emergency Use Authorization (EUA) of BNT162b2.

Also, the companies will submit data to the European Medicines Agency (EMA) for EU Conditional Marketing Authorization for COMIRNATY® to expand use in children aged 12-15 years as soon as possible.

Moreover, the companies will continue monitoring all the participants for long-term protection as well as safety for an additional two years after the administration of the second dose.

Albert Bourla, Chairman and CEO of Pfizer, commented:

Phase 3 clinical trial information

  • In the trial, 2,260 participants aged between 12 to 15 years were enrolled in the US.
  • Vaccination with BNT162b2 stimulated the neutralizing antibody against SARS-CoV-2 and demonstrated robust immunogenicity in a subset of adolescents one month after administering the second dose.
  • Further, BNT162b2 was well-tolerated, with side effects remaining the same as those seen in 16 to 25 years participants.

Phase 1/2/3 Study 6 months-11 years old Children

Recently, the two partners commenced dosing in a global Phase 1/2/3 clinical trial with the vaccine administered to the first healthy children.  

In this clinical trial, the companies will further evaluate BNT162b2’s safety, tolerability, and immunogenicity in the participants of 6 months to 11 years.

© Spukkato |

The duo disclosed that the trial is evaluating the vaccine on a two-dose schedule (almost 21 days apart) in three age groups-

  • Children aged 5 to 11 years.
  • Children aged 2 to 5 years
  • Children aged 6 months to 2 years.



The website is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK